Chimeric antigen receptor (CAR) T cell therapy mediates unprecedented benefit in certain leukemias and lymphomas, but has yet to achieve similar success in combating solid tumors. A substantial body of work indicates that the accumulation of adenosine in the solid tumor microenvironment (TME) plays a crucial role in abrogating immunotherapies. Adenosine deaminase 1 (ADA) catabolizes adenosine into inosine and is indispensable for a functional immune system. We have, for the first time, engineered CAR T cells to overexpress ADA. To potentially improve the pharmacokinetic profile of ADA, we have modified the overexpressed ADA in two ways, through the incorporation of a (1) albumin-binding domain or (2) collagen-binding domain. ADA and modified ADA were successfully expressed by CAR T cells and augmented CAR T cell exhaustion resistance. In a preclinical engineered ovarian carcinoma xenograft model, ADA and collagen-binding ADA overexpression significantly enhanced CAR T cell expansion, tumor tissue infiltration, tumor growth control, and overall survival, whereas albumin-binding ADA overexpression did not. Furthermore, in a syngeneic colon cancer solid tumor model, the overexpression of mouse ADA by cancer cells significantly reduced tumor burden and remodeled the TME to favor antitumor immunity. The overexpression of ADA for enhanced cell therapy is a safe, straightforward, reproducible genetic modification that can be utilized in current CAR T cell constructs to result in an armored CAR T product with superior therapeutic potential.
Get full access to this article
View all access options for this article.
References
1.
PorterDL, LevineBL, KalosM, et al.Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N Engl J Med, 2011; 365:725–733.
2.
DavilaML, RiviereI, WangX, et al.Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 2014; 6:224ra25.
3.
NeelapuSS, LockeFL, BartlettNL, et al.Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med, 2017; 377:2531–2544.
4.
GagelmannN, RieckenK, WolschkeC, et al.Development of CAR-T cell therapies for multiple myeloma. Leukemia, 2020; 34:2317–2332.
5.
NewickK, O'BrienS, MoonE, et al.CAR T cell therapy for solid tumors. Annu Rev Med, 2017; 68:139–152.
6.
GrigorEJ., FergussonD, KekreN, et al.Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transf Med Rev, 2019; 33:98–110.
7.
FucàG, ReppelL, LandoniE, et al.Enhancing chimeric antigen receptor T-cell efficacy in solid tumors. Clin Cancer Res, 2020; 26:2444–2451.
8.
MoonEK, WangL-C, JuneCH, et al.Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor—transduced human T cells in solid tumors. Clin Cancer Res, 2014; 20:4262–4273.
9.
BeattyGL, MoonEK. Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. Oncoimmunology, 2014; 3:e970027–e970027.
10.
LiH, FanX, HoughtonJ. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem, 2007; 101:805–815.
11.
WhitesideTL.The tumor microenvironment and its role in promoting tumor growth. Oncogene, 2008; 27:5904–5912.
12.
JoyceJA, FearonDT. T cell exclusion, immune privilege, and the tumor microenvironment. Science, 2015; 348:74–80.
13.
StaggJ, SmythMJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene, 2010; 29:5346–5358.
14.
AllardB, BeavisPA, DarcyPK, et al.Immunosuppressive activities of adenosine in cancer. Curr Opin Pharmacol, 2016; 29:7–16.
15.
LeoneRD, EmensLA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer, 2018; 6:57–57.
16.
SitkovskyM, OhtaA. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature, 2001; 414:916–920.
17.
BlayJ, WhiteTD, HoskinDW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res, 1997; 57:2602–2605.
18.
OhtaA, GorelikE, PrasadSJ, et al.A2A adenosine receptor protects tumors from antitumor T cells. PNAS, 2006; 103:13132–13137.
19.
JinD, FanJ, WangL, et al.CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res, 2010; 70:2245–2255.
20.
BastidJ, Cottalorda-RegairazA, AlbericiG, et al.ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene, 2013; 32:1743–1751.
21.
AllardB, AllardD, BuisseretL, et al.The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol, 2020; 17:611–629.
22.
CronsteinB, PacherP, HaskóG, et al.Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov, 2008; 7:759–770.
23.
HuangS, ApasovS, KoshibaM, et al.Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood, 1997; 90:1600–1610.
24.
LappasCM, RiegerJM, LindenJ. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol, 2005; 174:1073–1080.
25.
RaskovalovaT, LokshinA, HuangX, et al.Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res, 2007; 67:5949–5956.
26.
CsókaB, HimerL, SelmeczyZ, et al.Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J, 2008; 22:3491–3499.
27.
Mastelic-GavilletB, Navarro RodrigoB, DécombazL, et al.Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8 + T cells. J Immunother Cancer, 2019; 7:257–257.
28.
BastidJ, RegairazA, BonnefoyN, et al.Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res, 2015; 3:254–265.
29.
YegutkinGG, Marttila-IchiharaF, KarikoskiM, et al.Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur J Immunol, 2011; 41:1231–1241.
30.
BeavisPA, DivisekeraU, PagetC, et al.Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci, 2013; 110:14711–14716.
31.
CekicC, LindenJ. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment. Cancer Res, 2014; 74:7239–7249.
BeavisPA, HendersonMA, GiuffridaL, et al.Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest, 2017; 127:929–941.
34.
ParkmanR, GelfandEW, RosenFS, et al.Severe combined immunodeficiency and adenosine deaminase deficiency. N Engl J Med, 1975; 292:714–719.
35.
WhitmoreKV, GasparHB. Adenosine deaminase deficiency—more than just an immunodeficiency. Front Immunol, 2016; 7:314–314.
36.
KameokaJ, TanakaT, NojimaY, et al.Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science, 1993; 261:466–469.
37.
DavisS, AbuchowskiA, ParkYK, et al.Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin Exp Immunol, 1981; 46:649–652.
38.
ZorziA, LincianoS, AngeliniA. Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics. Med Chem Comm, 2019; 1:168–181.
39.
DennisMS, ZhangM, MengYG, et al.Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem, 2002; 277:35035–35043.
40.
NagyJA, ChangS-H, DvorakAM, et al.Why are tumour blood vessels abnormal and why is it important to know?. Br J Cancer, 2009; 100:865–869.
41.
LiangH, LiX, ChenB, et al.A collagen-binding EGFR single-chain Fv antibody fragment for the targeted cancer therapy. J Control Release, 2015; 209:101–109.
42.
ZhouZ, JiC, XiaoH, et al.Reorganized collagen in the tumor microenvironment of gastric cancer and its association with prognosis. J Cancer, 2017; 8:1466–1476.
43.
ShahidiM.Thrombosis and von Willebrand Factor. Adv Exp Med Biol, 2017; 906:285–306.
44.
IshiharaJ, IshiharaA, SasakiK, et al.Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci Transl Med, 2019; 11:eaau3259.
45.
SiriwonN, KimYJ, SieglerE, et al.CAR-T cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction. Cancer Immunol Res, 2018; 6:812–824.
46.
MartinM, HuguetJ, CentellesJ, et al.Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. Possible role of adenosine deaminase as costimulatory molecule. J Immunol, 1995; 155:4630–4643.
47.
PachecoR, Martinez-NavioJM, LejeuneM, et al.CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci, 2005; 102:9583–9588.
48.
NewickK, O'BrienS, SunJ, et al.Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase A localization. Cancer Immunol Res, 2016; 4:541–551.
49.
DiskinB, AdamS, CassiniMF, et al.PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Nat Immunol, 2020; 21:442–454.
50.
LeoneRD, SunI-M, OhM-H, et al.Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models. Cancer Immunol Immunother, 2018; 67:1271–1284.
51.
ZarekPE, HuangC-T, LutzER, et al.A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood, 2008; 111:251–259.
52.
OhtaA, KiniR, OhtaA, et al.The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol, 2012; 3:190–190.
53.
Dutsch-WicherekMM, SzubertS, DziobekK, et al.Analysis of the treg cell population in the peripheral blood of ovarian cancer patients in relation to the long-term outcomes. Ginekologia Polska, 2019; 90:179–184.
54.
KumagaiS, TogashiY, KamadaT, et al.The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol, 2020; 21:1346–1358.
55.
HoogenboezemEN, DuvallCL. Harnessing albumin as a carrier for cancer therapies. Adv Drug Deliv Rev, 2018; 130:73–89.
56.
MaoH, HajdukPJ, CraigR, et al.Rational design of diflunisal analogues with reduced affinity for human serum albumin. J Am Chem Soc, 2001; 123:10429–10435.
57.
MiZ, MalakH, BurkeTG. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry (Easton), 1995; 34:13722–13728.
58.
WangL, CowellJ, RosengrenS, et al.Abstract 1472: enzymatic depletion of adenosine by pegylated, engineered adenosine deaminase 2 (PEG-ADA2): a novel immunotherapeutic approach to treat solid tumors. Cancer Res, 2016; 76(14Supplement):1472–1472.
59.
SerraS, BolognaC, LondonoL, et al.Abstract 5583: pegylated adenosine deaminase 2 (PEG-ADA2) abrogates the cytoprotective effects of adenosine against chronic lymphocytic leukemia cells. Cancer Res, 2017; 77(13Supplement):5583–5583.
60.
MeytsI, AksentijevichI. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol, 2018; 38:569–578.
61.
ZhouW, GuminaG, ChongY, et al.Synthesis, structure−activity relationships, and drug resistance of β-d-3′-Fluoro-2′,3′-unsaturated nucleosides as anti-HIV agents. J Med Chem, 2004; 47:3399–3408.
62.
BlaeseRM, CulverKW, MillerAD, et al.T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science, 1995; 270:475–480.
63.
Kutryb-ZajacB, KoszalkaP, et al.Adenosine deaminase inhibition suppresses progression of 4T1 murine breast cancer by adenosine receptor-dependent mechanisms. J Cell Mol Med, 2018; 22:5939–5954.
64.
HaskóG, SitkovskyMV, SzabóC. Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci, 2004; 25:152–157.
65.
WangT, GnanaprakasamJNR, ChenX, et al.Inosine is an alternative carbon source for CD8 + -T-cell function under glucose restriction. Nat Metab, 2020; 2:635–647.
66.
MagerLF, BurkhardR, PettN, et al.Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science, 2020; 369:1481–1489.
67.
WelihindaAA, KaurM, GreeneK, et al.The adenosine metabolite inosine is a functional agonist of the adenosine A2A receptor with a unique signaling bias. Cell Signal, 2016; 28:552–560.
68.
WelihindaAA, KaurM, RaveendranKS, et al.Enhancement of inosine-mediated A2AR signaling through positive allosteric modulation. Cell Signal, 2018; 42:227–235.
69.
HäuslerSFM, Montalbán del BarrioI, StrohscheinJ, et al.Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer ImmunolImmunother, 2011; 60:1405–1418.
70.
TurcotteM, SpringK, PommeyS, et al.CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res, 2015; 75:4494–4503.
71.
BonoMR, FernándezD, Flores-SantibáñezF, et al.CD73 and CD39 ectonucleotidases in T cell differentiation: beyond immunosuppression. FEBS Lett, 2015; 589:3454–3460.
72.
DesrosiersMD, CembrolaKM, FakirMJ, et al.Adenosine deamination sustains dendritic cell activation in inflammation. J Immunol, 2007; 179:1884–1892.
73.
ViganoS, AlatzoglouD, IrvingM, et al.Targeting adenosine in cancer immunotherapy to enhance T-cell function. Front Immunol, 2019; 10:925–925.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
